GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ChemoMetec AS (FRA:CHY) » Definitions » Return-on-Tangible-Equity

ChemoMetec AS (FRA:CHY) Return-on-Tangible-Equity : 29.78% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is ChemoMetec AS Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ChemoMetec AS's annualized net income for the quarter that ended in Jun. 2024 was €17.61 Mil. ChemoMetec AS's average shareholder tangible equity for the quarter that ended in Jun. 2024 was €59.15 Mil. Therefore, ChemoMetec AS's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 was 29.78%.

The historical rank and industry rank for ChemoMetec AS's Return-on-Tangible-Equity or its related term are showing as below:

FRA:CHY' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 23.04   Med: 45.2   Max: 64.19
Current: 30.61

During the past 13 years, ChemoMetec AS's highest Return-on-Tangible-Equity was 64.19%. The lowest was 23.04%. And the median was 45.20%.

FRA:CHY's Return-on-Tangible-Equity is ranked better than
91.15% of 757 companies
in the Medical Devices & Instruments industry
Industry Median: 2.12 vs FRA:CHY: 30.61

ChemoMetec AS Return-on-Tangible-Equity Historical Data

The historical data trend for ChemoMetec AS's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoMetec AS Return-on-Tangible-Equity Chart

ChemoMetec AS Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.36 49.35 64.17 48.08 29.46

ChemoMetec AS Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.26 62.68 35.01 32.61 29.78

Competitive Comparison of ChemoMetec AS's Return-on-Tangible-Equity

For the Medical Devices subindustry, ChemoMetec AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoMetec AS's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where ChemoMetec AS's Return-on-Tangible-Equity falls into.



ChemoMetec AS Return-on-Tangible-Equity Calculation

ChemoMetec AS's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=18.26/( (60.896+63.076 )/ 2 )
=18.26/61.986
=29.46 %

ChemoMetec AS's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=17.614/( (55.218+63.076)/ 2 )
=17.614/59.147
=29.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


ChemoMetec AS  (FRA:CHY) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


ChemoMetec AS Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of ChemoMetec AS's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoMetec AS Business Description

Traded in Other Exchanges
Address
Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.